Quantification of 11 Cyohimbine binding to α 2 adrenoceptors in rat brain in vivo

Journal of Perinatology

Volumn 35, Issue 3, 2015, Pages 501-511

  Phan, Jenny Ann ^a,b   Landau, Anne M ^a,b   Wong, Dean F ^c,d,e   Jakobsen, Steen ^a   Nahimi, Adjmal ^a,e   Doudet, Doris J ^a,f   Gjedde, Albert ^b,c,e,g  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d DEPARTMENT OF PATHOLOGY   (United States)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^g MCGILL UNIVERSITY   (Canada)

Author keywords

alpha 2 adrenoceptors; amphetamine challenge; Inhibition plot; reference region; 11C yohimbine

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR; AMPHETAMINE; NORADRENALIN; UNCLASSIFIED DRUG; YOHIMBINE; YOHIMBINE C 11; CARBON; RADIOPHARMACEUTICAL AGENT;

ANIMAL EXPERIMENT; ARTICLE; BRAIN; CEREBELLUM; CONTROLLED STUDY; CORPUS STRIATUM; FRONTAL CORTEX; IN VIVO STUDY; NEUROTRANSMISSION; NONHUMAN; NORADRENERGIC SYSTEM; PLASMA; PONS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN BINDING; RAT; SENSITIVITY ANALYSIS; THALAMUS; VOLUME OF DISTRIBUTION; ANIMAL; METABOLISM; PAUSINYSTALIA; PROCEDURES; SCINTISCANNING; SPRAGUE DAWLEY RAT;

ANIMALS; BRAIN; CARBON RADIOISOTOPES; PAUSINYSTALIA; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ADRENERGIC, ALPHA-2;

EID: 84937520203     PISSN: 07438346     EISSN: 14765543     Source Type: Journal    
DOI: 10.1038/jcbfm.2014.225     Document Type: Article

References (40)

1. Garcia-Sevilla JA, Escriba PV, Ozaita A, La Harpe R, Walzer C, Eytan A et al. Up-regulation of immunolabeled alpha2A-Adrenoceptors, Gi coupling proteins, and regulatory receptor kinases in the prefrontal cortex of depressed suicides. J Neurochem 1999; 72: 282-291.
2. Szot P, White SS, Greenup JL, Leverenz JB, Peskind ER, Raskind MA. Compensatory changes in the noradrenergic nervous system in the locus ceruleus and hippocampus of postmortem subjects with Alzheimer's disease and dementia with Lewy bodies. J Neurosci 2006; 26: 467-478.
3. Tam SW, Worcel M, Wyllie M. Yohimbine: a clinical review. Pharmacol Ther 2001; 91: 215-243.
4. Millan MJ, Newman-Tancredi A, Audinot V, Cussac D, Lejeune F, Nicolas JP et al. Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha (2)-Adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT1B, 5-HT1D and dopamine D-2 and D-3 receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive states. Synapse 2000; 35: 79-95.
5. Jakobsen S, Pedersen K, Smith DF, Jensen SB, Munk OL, Cumming P. Detection of alpha2-Adrenergic receptors in brain of living pig with 11C-yohimbine. J Nucl Med 2006; 47: 2008-2015.
6. Landau AM, Doudet DJ, Jakobsen S. Amphetamine challenge decreases yohimbine binding to alpha2 adrenoceptors in Landrace pig brain. Psychopharmacology (Berl) 2012; 222: 155-163.
7. Logan J, Volkow ND, Fowler JS, Wang GJ, Dewey SL, Macgregor R et al. Effects of blood-flow on [C-11] raclopride binding in the brain-model simulations and kinetic-Analysis of pet data. J Cereb Blood Flow Metab 1994; 14: 995-1010.
8. Gjedde A, Wong D, Wagner H. Transient analysis of irreversible and reversible tracer binding in human brain. In: Battistin L, Gerstenbrand F (eds). PET and NMR: New Perspectives in Neuroimaging and in Clinical Neurochemistry. Alan R Liss: New York, NY, USA, 1986; 223-235.
9. Gjedde A, Wong DF. Receptor occupancy in absence of reference region. Neuroimage 2000; 11: S48.
10. Jones SR, Gainetdinov RR, Wightman RM, Caron MG. Mechanisms of amphetamine action revealed in mice lacking the dopamine transporter. J Neurosci 1998; 18: 1979-1986.
11. Logan J, Fowler JS, Volkow ND, Wolf AP, Dewey SL, Schlyer DJ et al. Graphical analysis of reversible radioligand binding from time-Activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab 1990; 10: 740-747.
12. Reith J, Dyve S, Kuwabara H, Guttman M, Diksic M, Gjedde A. Blood-brain transfer and metabolism of 6-[18F]fluoro-L-Dopa in rat. J Cereb Blood Flow Metab 1990; 10: 707-719.
13. Gjedde A, Gee A, Smith D. Basic CNS drug transport and binding kinetics in vivo. Begley DJ, Bradbury MW, Kreuter J (eds). The Blood-Brain Barrier and Drug Delivery to the CNS. Marcel Dekker: New York, NY, USA, 2000; 225-242.
14. Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 2007; 27: 1533-1539.
15. Lassen NA, Bartenstein PA, Lammertsma AA, Prevett MC, Turton DR, Luthra SK et al. Benzodiazepine receptor quantification in vivo in humans using [11C]flumazenil and PET: application of the steady-state principle. J Cereb Blood Flow Metab 1995; 15: 152-165.
16. Cunningham VJ, Rabiner EA, Slifstein M, Laruelle M, Gunn RN. Measuring drug occupancy in the absence of a reference region: the Lassen plot re-visited. J Cereb Blood Flow Metab 2010; 30: 46-50.
17. Shekim WO, Bylund DB, Hodges K, Glaser R, Ray-Prenger C, Oetting G. Platelet alpha 2-Adrenergic receptor binding and the effects of d-Amphetamine in boys with attention deficit hyperactivity disorder. Neuropsychobiology 1994; 29: 120-124.
18. Tanaka C, Kawai R, Rowland M. Dose-Dependent pharmacokinetics of cyclosporin A in rats: events in tissues. Drug Metab Dispos 2000; 28: 582-589.
19. Gandelman MS, Baldwin RM, Zoghbi SS, Zea-Ponce Y, Innis RB. Evaluation of ultrafiltration for the free-fraction determination of single photon emission computed tomography (SPECT) radiotracers: beta-CIT, IBF, and iomazenil. J Pharm Sci 1994; 83: 1014-1019.
20. Lavyne MH, Koltun WA, Clement JA, Rosene DL, Pickren KS, Zervas NT et al. Decrease in neostriatal blood flow after D-Amphetamine administration or electrical stimulation of the substantia nigra. Brain Res 1977; 135: 77-86.
21. Raichle ME, Hartman BK, Eichling JO, Sharpe LG. Central noradrenergic regulation of cerebral blood flow and vascular permeability. Proc Natl Acad Sci USA 1975; 72: 3726-3730.
22. Zhou Y, Ye W, Brasic JR, Wong DF. Multi-graphical analysis of dynamic PET. Neuroimage 2010; 49: 2947-2957.
23. Rouot B, Quennedey MC, Schwartz J. Characteristics of the [H-3]-labeled yohimbine binding on rat-brain alpha-2-Adrenoceptors. Naunyn Schmiedebergs Arch Pharmacol 1982; 321: 253-259.
24. Bylund DB. Subtypes of alpha 2-Adrenoceptors: pharmacological and molecular biological evidence converge. Trends Pharmacol Sci 1988; 9: 356-361.
25. Scheinin M, Lomasney JW, Hayden-Hixson DM, Schambra UB, Caron MG, Lefkowitz RJ et al. Distribution of alpha 2-Adrenergic receptor subtype gene expression in rat brain. Brain Res Mol Brain Res 1994; 21: 133-149.
26. Ordway GA, Jaconetta SM, Halaris AE. Characterization of subtypes of alpha-2 adrenoceptors in the human brain. J Pharmacol Exp Ther 1993; 264: 967-976.
27. Boyajian CL, Leslie FM. Pharmacological evidence for alpha-2 adrenoceptor heterogeneity: differential binding properties of [3H]rauwolscine and [3H]idazoxan in rat brain. J Pharmacol Exp Ther 1987; 241: 1092-1098.
28. Eschenko O, Evrard HC, Neves RM, Beyerlein M, Murayama Y, Logothetis NK. Tracing of noradrenergic projections using manganese-enhanced MRI. Neuroimage 2012; 59: 3252-3265.
29. Boyajian CL, Loughlin SE, Leslie FM. Anatomical evidence for alpha-2 adrenoceptor heterogeneity: differential autoradiographic distributions of [3H]rauwolscine and [3H]idazoxan in rat brain. J Pharmacol Exp Ther 1987; 241: 1079-1091.
30. Cornil CA, Castelino CB, Ball GF. Dopamine binds to alpha(2)-Adrenergic receptors in the song control system of zebra finches (Taeniopygia guttata). J Chem Neuroanat 2008; 35: 202-215.
31. Zhang W, Klimek V, Farley JT, Zhu MY, Ordway GA. alpha2C adrenoceptors inhibit adenylyl cyclase in mouse striatum: potential activation by dopamine. J Pharmacol Exp Ther 1999; 289: 1286-1292.
32. Tyacke RJ, Robinson ES, Lalies MD, Hume SP, Hudson AL, Nutt DJ. Estimation of endogenous noradrenaline release in rat brain in vivo using [3H]RX 821002. Synapse 2005; 55: 126-132.
33. O'Rourke MF, Blaxall HS, Iversen LJ, Bylund DB. Characterization of [3H]RX821002 binding to alpha-2 adrenergic receptor subtypes. J Pharmacol Exp Ther 1994; 268: 1362-1367.
34. Watkins PB. The role of cytochromes P-450 in cyclosporine metabolism. J Am Acad Dermatol 1990; 23: 1301-1309, discussion 1309-1311.
35. Kraemer T, Maurer HH. Toxicokinetics of amphetamines: metabolism and toxicokinetic data of designer drugs, amphetamine, methamphetamine, and their N-Alkyl derivatives. Ther Drug Monit 2002; 24: 277-289.
36. Yang H, Elmquist WF. The binding of cyclosporin A to human plasma: an in vitro microdialysis study. Pharm Res 1996; 13: 622-627.
37. Le Corre P, Parmer RJ, Kailasam MT, Kennedy BP, Skaar TP, Ho H et al. Human sympathetic activation by alpha2-Adrenergic blockade with yohimbine: bimodal, epistatic influence of cytochrome P450-mediated drug metabolism. Clin Pharmacol Ther 2004; 76: 139-153.
38. Warner M, Kohler C, Hansson T, Gustafsson JA. Regional distribution of cytochrome P-450 in the rat brain: spectral quantitation and contribution of P-450b,e, and P-450c,d. J Neurochem 1988; 50: 1057-1065.
39. Anzawa N, Kushikata T, Ohkawa H, Yoshida H, Kubota T, Matsuki A. Increased noradrenaline release from rat preoptic area during and after sevoflurane and isoflurane anesthesia. Can J Anaesth 2001; 48: 462-465.
40. McCormick PN, Ginovart N, Wilson AA. Isoflurane anaesthesia differentially affects the amphetamine sensitivity of agonist and antagonist D2/D3 positron emission tomography radiotracers: implications for in vivo imaging of dopamine release. Mol Imaging Biol 2011; 13: 737-746.